Approximately 28,436 bottles of Triamterene and Hydrochlorothiazide tablets (37.5 mg/25 mg) are being recalled because the medication was found to be subpotent. This defect means the tablets contain less of the active ingredient than they should, which can prevent the medication from working effectively to treat high blood pressure or fluid retention. The recall affects 100-count prescription bottles that were distributed nationwide within the United States.
Subpotent medication may lead to inadequate treatment of a patient's medical condition, such as uncontrolled high blood pressure or increased swelling (edema), because the patient is not receiving the full intended dose. While no specific injuries were reported, patients rely on these dosages for consistent health management.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.